Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic, Inc. (HOLX) reported preliminary revenue results for Q1 FY2023, estimating revenues of approximately
Hologic, Inc. (NASDAQ: HOLX) will announce its financial results for Q1 FY2023 on February 1, after market closure. A conference call will follow at 4:30 PM ET. Interested parties can participate via phone or by accessing the webcast on Hologic's investor relations website. A replay will be available for 30 days. Hologic focuses on enhancing women's health through innovative medical technology solutions.
Hologic, Inc. (NASDAQ: HOLX) announced its upcoming presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time. The event will include a live webcast accessible on Hologic's Investors website, which will remain available for 30 days post-event. Hologic focuses on enhancing women's health through innovative medical technologies, emphasizing early detection and treatment.
Hologic, Inc. (NASDAQ: HOLX) has appointed Stacey D. Stewart to its Board of Directors and the Audit and Finance Committee, effective January 2, 2023. Ms. Stewart, who has been the President and CEO of March of Dimes since November 2016, is set to depart from the organization by year-end. With a strong background in finance and healthcare, her appointment is expected to enhance the operational expertise of the board. Chairman Steve MacMillan emphasized her experience with purpose-driven organizations as a significant asset for Hologic.
Hologic and its subsidiary Biotheranostics announced groundbreaking results at the 2022 San Antonio Breast Cancer Symposium, revealing that the Breast Cancer Index test effectively predicts treatment benefits from ovarian function suppression for premenopausal patients with early-stage HR+ breast cancer. The test identified 58% of patients who benefitted from combining ovarian function suppression with endocrine therapy, showing a significant absolute benefit of 11.6%. This data supports the test's role in personalized treatment approaches in oncology.
Hologic, Inc. (NASDAQ: HOLX) has been awarded three IMV ServiceTrak™ Awards for Mammography during RSNA 2022, marking its 10th consecutive year receiving top honors for service, customer satisfaction, and system performance. The company is recognized for its Genius® 3D Mammography™ exam, which is FDA-approved for enhanced detection of breast cancer. Hologic's SureCare® Service offers comprehensive support to customers, ensuring optimal system performance. This recognition highlights Hologic's commitment to excellence in women's health technology.
Hologic, Inc. (NASDAQ: HOLX) will showcase its breast and skeletal health products, including the new Affirm Contrast Biopsy technology, at the RSNA 2022 meeting in Chicago from Nov. 27 to Dec. 1. This technology offers a cost-effective alternative to traditional breast MRI for biopsy procedures, addressing the needs of clinicians and patients. A recent study indicated that 98% of patients had a positive experience using the software. Hologic is committed to advancing breast care through innovative solutions and will also host educational symposiums on related topics.
Hologic, Inc. (NASDAQ: HOLX) will present virtually at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 2:40 p.m. Eastern Time. The fire-side chat will be streamed live and can be accessed through the investor section of Hologic's website. The webcast will remain available for 30 days post-event. Hologic specializes in innovative medical technology, focusing on enhancing women's health through early detection and treatment.
Hologic, Inc. (Nasdaq: HOLX) has announced that its 3Dimensions™ mammography system received EUREF Type Test certification, making it the first digital breast tomosynthesis system to achieve this distinction. This certification verifies that the system meets stringent European standards for image quality and radiation exposure. The 3Dimensions system provides enhanced patient comfort, improved workflow for radiologists, and is recognized for its high resolution and speed. This achievement highlights Hologic's commitment to advancing women's health through innovative technology.
Hologic, Inc. (NASDAQ: HOLX) has secured a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to enhance its SARS-CoV-2 diagnostics. This funding aims to align Hologic's Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Aptima® SARS-CoV-2 assay with FDA in vitro diagnostic standards. The Panther Fusion assay, currently under U.S. development after receiving CE-marking in May 2022, will further clinical efforts for nasal sample claims and market authorization for asymptomatic COVID-19 testing.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
